Importantly, no changes were observed in the Aβ42/Aβ40 ratio, or any other tested AD biomarker (i.e., p-tau217, p-tau231, p-tau181, NfL and GFAP) either in CSF or plasma. The gene discussed is NEFL; the disease is Alzheimer disease.